세계의 건조증 시장 : 치료별, 원인별, 최종 사용자별(-2032년)

Market Overview

The Xerosis Market is expected to develop at a compound annual growth rate (CAGR) of 7.71% from 2024 to 2032. Xerosis, also known as xeroderma, is a skin disorder characterized by excessive dryness caused by over-cleansing, excessive showering, living in low-humidity areas, dehydration, prolonged sun exposure, ageing, and so on. Xerosis most typically affects the scalp, lower legs, arms, and thighs, with symptoms including scaling (visible peeling of the outer skin layer), itching, and skin cracking. Other symptoms include dry, itchy, and scaly skin, flaky skin, and irritated red skin. Xerosis is common throughout the winter because the cold, dry air causes the skin to lose moisture. Xerosis can also be caused by a vitamin A or vitamin D deficiency, systemic disease, or drug adverse effects. The conventional treatment for xerosis is to apply emollients, moisturizers, and so on.

Xerosis also responds favorable to lifestyle adjustments. Hormonal changes caused by aging, diabetes, and other conditions alter sweat and sebaceous glands, increasing the risk of Xerosis. Petrolatum, vegetable oils, mineral oil, and other highly occlusive skin barrier products produce good outcomes. Lanolin, a natural lipid obtained from sheep's wool, replaces the lipids found in human skin and is one of the most successful therapies for xeroderma. The main disadvantages of lanolin are that it is a common allergy and that it is a thick waxy substance that is difficult to apply.

Market Segmentation

The global xerosis market is categorized by therapy, cause, and end user.

The market is divided into therapeutic categories such as emollients, moisturizers, humidifiers, oils, and others.

The market has been classified into causes such as eczema, psoriasis, diabetes, hypothyroidism, aging, and others.

The market has been categorized by end users into hospitals, dermatological clinics, and home care.

Regional analysis.

The United States has the highest Xerosis market share because to increased medicine use and healthcare expenditure. The speedier market adoption of new technology and gadgets in the United States is another key driver of the Xerosis industry. Europe is the second largest market, owing to high disposable income and increased awareness. The Asia-Pacific area is predicted to have the biggest future potential, driven by China and India.

The Gulf nations, particularly Saudi Arabia and the United Arab Emirates, dominate the Middle East and Africa market. Africa's Xerosis market is predicted to develop moderately due to weak economic and political situations, as well as low healthcare penetration. Market Research Future's report on the Global Xerosis market includes extensive primary research as well as rigorous qualitative and quantitative analysis by various industry professionals and key opinion leaders to acquire a better understanding of the market and industry performance.

Key Players

Procter & Gamble, Alba Botanica, Avalon Organics, Johnson & Johnson Consumer Inc., Galderma Laboratories, Clarins, Unilever, Hempz, L'Oreal, Avon, Croda International Plc, Beiersdorf, Estee Lauder, United-Guardian, Inc., Dow Corning Corp., and others are the market leaders in Xerosis.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TYPE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 RISING AWARENESS AND IMPROVED DIAGNOSIS
  • 4.2.2 INNOVATIVE PRODUCT FORMULATIONS
  • 4.2.3 RISE IN DISPOSABLE INCOME AND SPENDING ON SKINCARE
• 4.3 RESTRAINTS
  • 4.3.1 SIDE EFFECTS ASSOCIATED WITH THE XEROSIS TREATMENT DRUGS
• 4.4 OPPORTUNITY
  • 4.4.1 GROWING GERIATRIC POPULATION
  • 4.4.2 INCREASE IN SELF-CARE PRACTICES FOR XEROSIS
  • 4.4.3 ONGOING CLINICAL TRIALS AND UNIVERSITIES STUDIES

MARKET FACTOR ANALYSIS

• 4.5 PORTER'S FIVE FORCES MODEL
  • 4.5.1 THREAT OF NEW ENTRANTS
  • 4.5.2 BARGAINING POWER OF SUPPLIERS
  • 4.5.3 THREAT OF SUBSTITUTES
  • 4.5.4 BARGAINING POWER OF BUYERS
  • 4.5.5 INTENSITY OF RIVALRY
• 4.6 IMPACT OF COVID-19 ON GLOBAL XEROSIS TREATMENT MARKET
• 4.7 EPIDEMIOLOGY ANALYSIS
• 4.8 MARKET TRENDS

5 GLOBAL XEROSIS TREATMENT MARKET, BY TYPE

• 5.1 OVERVIEW
• 5.2 MEDICATION
  • 5.2.1 ANTIHISTAMINES
  • 5.2.2 CORTICOSTEROIDS
  • 5.2.3 CALCINEURIN INHIBITORS
  • 5.2.4 ANTI-INFLAMMATORY
  • 5.2.5 IMMUNOMODULATORS
  • 5.2.6 OTHERS
• 5.3 PERSONAL CARE PRODUCTS

6 GLOBAL XEROSIS TREATMENT MARKET, BY FORM

• 6.1 OVERVIEW
• 6.2 TABLETS
• 6.3 LOTION
• 6.4 CREAM
• 6.5 OINTMENT
• 6.6 SHOWER FOAMS
• 6.7 OTHERS

7 GLOBAL XEROSIS TREATMENT MARKET, BY AGE GROUP

• 7.1 OVERVIEW
• 7.2 PAEDIATRICS
• 7.3 ADULTS
• 7.4 ELDERLY

8 GLOBAL XEROSIS TREATMENT MARKET, BY GENDER

• 8.1 OVERVIEW
• 8.2 MALE
• 8.3 FEMALE

9 GLOBAL XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

• 9.1 OVERVIEW
• 9.2 ONLINE
• 9.3 OFFLINE

10 GLOBAL XEROSIS TREATMENT MARKET, BY REGION

• 10.1 OVERVIEW
• 10.2 NORTH AMERICA
  • 10.2.1 US
  • 10.2.2 CANADA
• 10.3 EUROPE
  • 10.3.1 GERMANY
  • 10.3.2 FRANCE
  • 10.3.3 UK
  • 10.3.4 SPAIN
  • 10.3.5 ITALY
  • 10.3.6 RUSSIA
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 CHINA
  • 10.4.2 INDIA
  • 10.4.3 JAPAN
  • 10.4.4 SOUTH KOREA
  • 10.4.5 MALAYSIA
  • 10.4.6 THAILAND
  • 10.4.7 INDONESIA
  • 10.4.8 REST OF ASIA PACIFIC
• 10.5 SOUTH AMERICA
  • 10.5.1 BRAZIL
  • 10.5.2 MEXICO
  • 10.5.3 ARGENTINA
  • 10.5.4 REST OF SOUTH AMERICA
• 10.6 MIDDLE EAST AND AFRICA
  • 10.6.1 GCC COUNTRIES
  • 10.6.2 SOUTH AFRICA
  • 10.6.3 REST OF MEA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 MARKET SHARE ANALYSIS, 2023
• 11.3 COMPETITOR DASHBOARD
• 11.4 PUBLIC PLAYERS STOCK SUMMARY
• 11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
• 11.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 11.1.1 PRODUCT LAUNCH

12 COMPANY PROFILES

• 12.1 AMGEN INC
  • 12.1.1 COMPANY OVERVIEW
  • 12.1.2 FINANCIAL OVERVIEW
  • 12.1.3 PRODUCTS OFFERED
  • 12.1.4 KEY DEVELOPMENTS
  • 12.1.5 SWOT ANALYSIS
  • 12.1.6 KEY STRATEGIES
• 12.2 PROCTER & GAMBLE
  • 12.2.1 COMPANY OVERVIEW
  • 12.2.2 FINANCIAL OVERVIEW
  • 12.2.3 PRODUCTS OFFERED
  • 12.2.4 KEY DEVELOPMENTS
  • 12.2.5 SWOT ANALYSIS
  • 12.2.6 KEY STRATEGIES
• 12.3 UNILEVER
  • 12.3.1 COMPANY OVERVIEW
  • 12.3.2 FINANCIAL OVERVIEW
  • 12.3.3 PRODUCTS OFFERED
  • 12.3.4 KEY DEVELOPMENTS
  • 12.3.5 KEY STRATEGIES
• 12.4 PFIZER INC.
  • 12.4.1 COMPANY OVERVIEW
  • 12.4.2 FINANCIAL OVERVIEW
  • 12.4.3 PRODUCTS OFFERED
  • 12.4.4 KEY DEVELOPMENTS
  • 12.4.5 SWOT ANALYSIS
  • 12.4.6 KEY STRATEGIES
• 12.5 CIPLA
  • 12.5.1 COMPANY OVERVIEW
  • 12.5.2 FINANCIAL OVERVIEW
  • 12.5.3 PRODUCTS OFFERED
  • 12.5.4 KEY DEVELOPMENTS
  • 12.5.5 KEY STRATEGIES
• 12.6 BAYER AG
  • 12.6.1 COMPANY OVERVIEW
  • 12.6.2 FINANCIAL OVERVIEW
  • 12.6.3 PRODUCTS OFFERED
  • 12.6.4 KEY DEVELOPMENTS
  • 12.6.5 SWOT ANALYSIS
  • 12.6.6 KEY STRATEGY
• 12.7 JOHNSON & JOHNSON INC.
  • 12.7.1 COMPANY OVERVIEW
  • 12.7.2 FINANCIAL OVERVIEW
  • 12.7.3 PRODUCTS OFFERED
  • 12.7.4 KEY DEVELOPMENTS
  • 12.7.5 SWOT ANALYSIS
  • 12.7.6 KEY STRATEGIES
• 12.8 GALDERMA
  • 12.8.1 COMPANY OVERVIEW
  • 12.8.2 FINANCIAL OVERVIEW
  • 12.8.3 PRODUCT OFFERED
  • 12.8.4 KEY DEVELOPMENTS
  • 12.8.5 KEY STRATEGIES
• 12.9 DR. REDDY'S LABORATORIES LTD.
  • 12.9.1 COMPANY OVERVIEW
  • 12.9.2 FINANCIAL OVERVIEW
  • 12.9.3 PRODUCT OFFERED
  • 12.9.4 KEY DEVELOPMENTS
  • 12.9.5 KEY STRATEGIES
• 12.10 THORNTON & ROSS LTD.
  • 12.10.1 COMPANY OVERVIEW
  • 12.10.2 FINANCIAL OVERVIEW
  • 12.10.3 PRODUCT OFFERED
  • 12.10.4 KEY DEVELOPMENTS
  • 12.10.5 KEY STRATEGIES

13 DATA CITATIONS